Alembic Pharmaceuticals Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012
January 21, 2013 at 08:38 am EST
Share
Alembic Pharmaceuticals Limited announced unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 3,688 million compared to INR 3,813.3 million a year ago. Total income from operations was INR 3,692.8 million compared to INR 3,821.2 million a year ago. Profit from operations before other income, interest, depreciation and exceptional items was INR 694 million compared to INR 684.8 million a year ago. Net profit from ordinary activities before tax was INR 600.9 million compared to INR 535.4 million a year ago. Net profit from ordinary activities after tax was INR 482.7 million compared to INR 442.3 million a year ago. Basic and diluted EPS was INR 2.56 compared to INR 2.35 a year ago.
For the nine months, on consolidated basis, the company reported net sales/income from operations of INR 11,406.7 million compared to INR 11,215.6 million a year ago. Total income from operations was INR 11,429.0 million compared to INR 11,237.8 million a year ago. Profit from operations before other income, interest, depreciation and exceptional items was INR 1,863.8 million compared to INR 1,793.0 million a year ago. Net profit from ordinary activities before tax was INR 1,511.7 million compared to INR 1,340.5 million a year ago. Net profit from ordinary activities after tax was INR 1,216.0 million compared to INR 1,098.3 million a year ago. Basic and diluted EPS was INR 6.45 compared to INR 5.83 a year ago.
For the quarter, on standalone basis, the company reported net sales/income from operations of INR 3,688 million compared to INR 3,491.1 million a year ago. Total income from operations was INR 3,692.8 million compared to INR 3,499 million a year ago. Profit from operations before other income, interest, depreciation and exceptional items was INR 702.4 million compared to INR 602.6 million a year ago. Net profit from ordinary activities before tax was INR 609.3 million compared to INR 453.2 million a year ago. Net profit from ordinary activities after tax was INR 490 million compared to INR 370.1 million a year ago. Basic and diluted EPS was INR 2.60 compared to INR 1.96 a year ago.
For the nine months, on standalone basis, the company reported net sales/income from operations of INR 11,133.1 million compared to INR 10,544.9 million a year ago. Total income from operations was INR 11,155.3 million compared to INR 10,567.1 million a year ago. Profit from operations before other income, interest, depreciation and exceptional items was INR 1,820.6 million compared to INR 1,700.6 million a year ago. Net profit from ordinary activities before tax was INR 1,468.6 million compared to INR 1,248.1 million a year ago. Net profit from ordinary activities after tax was INR 1,177.5 million compared to INR 1,016.4 million a year ago. Basic and diluted EPS was INR 6.25 compared to INR 5.39 a year ago.
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
Alembic Pharmaceuticals Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012